DE69232617T2 - Gefriergetrocknete Zubereitung, die einen monoklonalen Antikörper enthält - Google Patents

Gefriergetrocknete Zubereitung, die einen monoklonalen Antikörper enthält

Info

Publication number
DE69232617T2
DE69232617T2 DE69232617T DE69232617T DE69232617T2 DE 69232617 T2 DE69232617 T2 DE 69232617T2 DE 69232617 T DE69232617 T DE 69232617T DE 69232617 T DE69232617 T DE 69232617T DE 69232617 T2 DE69232617 T2 DE 69232617T2
Authority
DE
Germany
Prior art keywords
freeze
monoclonal antibody
preparation containing
dried preparation
dried
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69232617T
Other languages
English (en)
Other versions
DE69232617D1 (de
Inventor
Tamotsu Fukuda
Yasuyuki Kuroiwa
Yukio Shimazaki
Shiro Takagi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsui Chemicals Inc
Original Assignee
Mitsui Chemicals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12663510&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69232617(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsui Chemicals Inc filed Critical Mitsui Chemicals Inc
Publication of DE69232617D1 publication Critical patent/DE69232617D1/de
Application granted granted Critical
Publication of DE69232617T2 publication Critical patent/DE69232617T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69232617T 1991-03-08 1992-02-28 Gefriergetrocknete Zubereitung, die einen monoklonalen Antikörper enthält Expired - Fee Related DE69232617T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4343191 1991-03-08

Publications (2)

Publication Number Publication Date
DE69232617D1 DE69232617D1 (de) 2002-06-27
DE69232617T2 true DE69232617T2 (de) 2002-10-31

Family

ID=12663510

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69225757T Expired - Fee Related DE69225757T2 (de) 1991-03-08 1992-02-28 Lyophilische monoklonale antikörperpräparationen
DE69232617T Expired - Fee Related DE69232617T2 (de) 1991-03-08 1992-02-28 Gefriergetrocknete Zubereitung, die einen monoklonalen Antikörper enthält

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69225757T Expired - Fee Related DE69225757T2 (de) 1991-03-08 1992-02-28 Lyophilische monoklonale antikörperpräparationen

Country Status (10)

Country Link
US (1) US5908826A (de)
EP (2) EP0531539B1 (de)
JP (1) JPH0565233A (de)
AU (1) AU645187B2 (de)
CA (1) CA2082169A1 (de)
DE (2) DE69225757T2 (de)
DK (2) DK0531539T3 (de)
FI (1) FI924982A (de)
NO (1) NO924279D0 (de)
WO (1) WO1992015331A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JPH11510170A (ja) * 1995-07-27 1999-09-07 ジェネンテック インコーポレーテッド タンパク質の処方
JP2014148555A (ja) * 1995-07-27 2014-08-21 Genentech Inc タンパク質の処方
JP3624543B2 (ja) * 1996-05-02 2005-03-02 東ソー株式会社 免疫反応試薬及びその製造方法
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
AU2444899A (en) * 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
US6750330B1 (en) * 1998-05-14 2004-06-15 Ashley Davis Lyophilized tubulins
EP1254666A4 (de) * 1999-12-28 2004-12-22 Chugai Pharmaceutical Co Ltd Stabile antikörper zusammensetzungen und injektions formulierungen
EP1336410A4 (de) * 2000-08-04 2005-10-12 Chugai Pharmaceutical Co Ltd Protein-injektionszubereitungen
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
MXPA04000747A (es) * 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
PL2335725T3 (pl) 2003-04-04 2017-04-28 Genentech, Inc. Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
AU2004256354B2 (en) 2003-07-15 2011-07-07 Chugai Seiyaku Kabushiki Kaisha IgM production by transformed cells and methods for quantifying said IgM production
US7803914B2 (en) 2003-10-09 2010-09-28 Chugai Seiyaku Kabushiki Kaisha Methods for stabilizing protein solutions
WO2005035574A1 (ja) 2003-10-09 2005-04-21 Chugai Seiyaku Kabushiki Kaisha IgM高濃度安定化溶液
US20070184050A1 (en) * 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
EP1888637A2 (de) * 2005-05-19 2008-02-20 Amgen Inc. Zusammensetzungen und verfahren zur erhöhung der stabilität von antikörpern
AU2006259664A1 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
WO2007074880A1 (ja) * 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
MX2009003635A (es) * 2006-10-06 2009-04-22 Amgen Inc Formulaciones de anticuerpos estables.
MX2009003982A (es) * 2006-10-20 2009-04-27 Amgen Inc Formulaciones de polipeptido estables.
KR20090113340A (ko) * 2007-03-22 2009-10-29 임클론 엘엘씨 안정한 항체 제제
JP5322405B2 (ja) * 2007-06-07 2013-10-23 小林製薬株式会社 タンパク質含有組成物
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
KR101903931B1 (ko) 2010-03-01 2018-10-02 바이엘 헬스케어 엘엘씨 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 최적화된 모노클로날 항체
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
EP3542820A1 (de) 2010-11-05 2019-09-25 Novartis AG Verfahren zur behandlung von psoriasus-arthritis mit il-17 antagonisten
MX344727B (es) 2010-11-11 2017-01-05 Abbvie Biotechnology Ltd Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
JP2012158615A (ja) * 2012-05-28 2012-08-23 Kobayashi Pharmaceutical Co Ltd 還元糖によるタンパク質変性を抑制する方法
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
WO2015185998A2 (en) 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
US9937171B2 (en) 2014-04-11 2018-04-10 Acerta Pharma B.V. Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
WO2016024227A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
WO2016055982A1 (en) 2014-10-10 2016-04-14 Acerta Pharma B.V. Quinoline and quinazoline compounds
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
PL3334747T3 (pl) 2015-08-13 2024-04-02 Amgen Inc. Naładowana filtracja wgłębna białek wiążących antygen
WO2017077507A1 (en) 2015-11-06 2017-05-11 Acerta Pharma B.V. Imidazopyrazine inhibitors of bruton's tyrosine kinase

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2149304A (en) * 1936-04-20 1939-03-07 Sharp & Dohme Inc Lyophilic biologically active substances
SU700132A1 (ru) * 1978-06-30 1979-11-30 Томский Ордена Трудового Красного Знамени Научно-Исследовательский Институт Вакцин И Сывороток Способ получени сухого препарата иммуноглобулина
JPS57140724A (en) * 1981-02-25 1982-08-31 Green Cross Corp:The Heat-treatment of aqueous solution containing cold insoluble globulin
JPS58167518A (ja) * 1982-03-29 1983-10-03 Nippon Sekijiyuujishiya ゼラチン誘導体添加静注用人免疫グロブリンの製造法
JPS6035263A (ja) * 1983-08-05 1985-02-23 Wako Pure Chem Ind Ltd 不溶性担体に固定化された免疫活性物質の安定化法及び該物質を構成単位として含む生理活性物質測定用試薬
JPS60146833A (ja) * 1984-01-10 1985-08-02 Green Cross Corp:The モノクロ−ナル抗体製剤
JP2565303B2 (ja) * 1984-05-25 1996-12-18 三井東圧化学株式会社 緑膿菌感染症の予防治療剤
US4650772A (en) * 1984-08-09 1987-03-17 Abbott Laboratories Monoclonal antibody stabilization
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
JPS61176532A (ja) * 1985-01-30 1986-08-08 Green Cross Corp:The プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
JPH0825903B2 (ja) * 1985-05-16 1996-03-13 株式会社ミドリ十字 γ―グロブリン含有水溶液
JPS6178731A (ja) * 1985-05-20 1986-04-22 Green Cross Corp:The 加熱処理免疫グロブリン製剤
DE3619565A1 (de) * 1986-06-11 1987-12-17 Behringwerke Ag Verfahren zur herstellung einer pasteurisierten immunglobulinpraeparation
JPS6388197A (ja) * 1986-09-30 1988-04-19 Tosoh Corp モノクロナル抗体の安定化方法
KR910004868B1 (ko) * 1986-12-15 1991-07-15 미츠이 도아츠 가가쿠 가부시기가이샤 인체 단일 클론항체 및 그것을 활성성분으로 함유하는 감염증의 예방 및 치료용 약학적 제제
EP0303088B1 (de) * 1987-08-10 1992-11-11 Miles Inc. Gereinigtes IgM
JPH03504499A (ja) * 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
JPH04504253A (ja) * 1989-03-27 1992-07-30 セントカー・インコーポレーテツド ＩｇＭ抗体の安定化のための配合物
JPH0384461A (ja) * 1989-08-28 1991-04-10 Green Cross Corp:The 免疫学的凝集反応試薬及びその製法
JPH0911350A (ja) * 1995-06-30 1997-01-14 Olympus Optical Co Ltd エネルギー硬化型樹脂を用いた光学素子の製造方法

Also Published As

Publication number Publication date
EP0531539B1 (de) 1998-06-03
EP0531539A4 (de) 1995-04-05
FI924982A0 (fi) 1992-11-04
WO1992015331A1 (fr) 1992-09-17
EP0531539A1 (de) 1993-03-17
DE69232617D1 (de) 2002-06-27
EP0841067B1 (de) 2002-05-22
AU645187B2 (en) 1994-01-06
NO924279L (no) 1992-11-06
DE69225757D1 (de) 1998-07-09
US5908826A (en) 1999-06-01
FI924982A (fi) 1992-11-04
DE69225757T2 (de) 1998-12-03
CA2082169A1 (en) 1992-09-09
DK0841067T3 (da) 2002-07-15
NO924279D0 (no) 1992-11-06
JPH0565233A (ja) 1993-03-19
AU1337592A (en) 1992-10-06
EP0841067A1 (de) 1998-05-13
DK0531539T3 (da) 1998-10-12

Similar Documents

Publication Publication Date Title
DE69232617T2 (de) Gefriergetrocknete Zubereitung, die einen monoklonalen Antikörper enthält
DE69003568T2 (de) Arzneimittel mit verzögerter Freigabe.
EP0597829A4 (de) Monoklonaler antikörper gegen einen neuen mit menschlichen tumoren assoziierten antigen.
DE68914244D1 (de) Monoklonaler Antikörper.
CY2006001I1 (el) Ανθρωποποιημενο heregulin αντισωμα
EP0618929A4 (de) Bispezifische heterodimere antikörper.
DE69018801T2 (de) Chimärischer anti-cae-antikörper.
NZ236000A (en) Oligomeric monoclonal igg antibody composition
DK666389A (da) Monoklonalt antistof
EP0627932A4 (de) Neuartige antikörperkonstrukte.
DE3854502D1 (de) Gegen hiv-antigene spezifischer monoklonaler antikörper.
DE3885355D1 (de) Monoklonale Antikörper.
EP0580859A4 (en) Anti-eda monoclonal antibody
NO920523L (no) Ige-reseptor-antistoff
GB9204928D0 (en) Monoclonal antibody production
NO894444L (no) Anti-fucosylceramid monoklonalt antistoff.
GB9114468D0 (en) Antibody production
DE3780256D1 (de) Anti-pci-monoklonaler antikoerper.
DK474189A (da) Monoklonalt antistof
NO890116L (no) Monoklonale antistoffer.
DE69023717T2 (de) Monoklonaler Antikörper.
DE68912772T2 (de) Monoklonaler antikörper gegen entero-viren.
IT8821702A0 (it) Nuovo anticorpo monoclonale.
FI893928A0 (fi) Monoklonala motkroppar.
ZA928880B (en) Tumor associated monoclonal antibody 88BV59.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8339 Ceased/non-payment of the annual fee